Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2015, Vol. 6 Issue (3) : 168-173     DOI: 10.14336/AD.2014.0925
OriginalArticle |
Plasma Epidermal Growth Factor Decreased in the Early Stage of Parkinson’s Disease
Jiang Qian-Wen, Wang Cheng, Zhou Yi, Hou Miao-Miao, Wang Xi, Tang Hui-Dong, Wu Yi-Wen, Ma Jian-Fang*(), Chen Sheng-Di*()
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to ShanghaiJiao Tong University School of Medicine, Shanghai, 200025, China
Download: PDF(340 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Epidermal growth factor (EGF) is a neurotrophic factor that plays an important role in Parkinson’s disease (PD). We measured plasma EGF level in PD, essential tremor (ET) and normal controls toinvestigate whether it changes in PD and whether it is associated with motor and non-motor symptoms of PD. 100 patients with PD, 40 patients with ET as disease control and 76 healthy persons were enrolled in the present study. Motor and non-motor symptoms were assessed by different scales. Plasma EGF levels of three groups were measured by enzyme-linked immunosorbent assay kit. Spearman test and linear logistics regression model were used to test the correlation of EGF with motor and non-motor symptoms of PD. Plasma EGF level was significantly decreased in early PD patients compared with normal control, butnot in advanced PD patients. Interestingly, plasma EGF level was significantly increased in advanced PD and total PD patients compared with ET patients, but not in early PD patients. In addition, plasma EGF level was correlated with UPDRS-III scores in PD. Also plasma EGF level was correlated with UPDRS-III scores and NMS scores in early PD.Our results suggested that plasma EGF decreased in the early stage of PD and increased later on in the PD disease course. Also, plasma EGF level was increased significantly in PD compared with ET patients and correlated with motor and non-motor symptoms in early PD.

Keywords epidermal growth factor      Parkinson’s disease      essential tremor     
Corresponding Authors: Ma Jian-Fang,Chen Sheng-Di     E-mail: majifa@hotmail.com.;chen_sd@medmail.com.cnor
About author:

present address: Kunming Biomed International, Kunming, Yunnan, 650500, China

Issue Date: 01 June 2015
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Jiang Qian-Wen
Wang Cheng
Zhou Yi
Hou Miao-Miao
Wang Xi
Tang Hui-Dong
Wu Yi-Wen
Ma Jian-Fang
Chen Sheng-Di
Cite this article:   
Jiang Qian-Wen,Wang Cheng,Zhou Yi, et al. Plasma Epidermal Growth Factor Decreased in the Early Stage of Parkinson’s Disease[J]. Aging and disease, 2015, 6(3): 168-173.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2014.0925     OR     http://www.aginganddisease.org/EN/Y2015/V6/I3/168
Table 1  Demographic features and EGF level of PD, ET and controls
Table 2  Demographic features, clinical characteristics and serum EGF level in PD patients and control
Figure 1.  Correlation of plasma EGF with motor and non-motor symptoms of PD.A. Plasma EGF correlated with UPDRS-III scores in PD patients. B. Plasma EGF correlated with UPDRS-III scores in early PD. C. Plasma EGF correlated with NMS scores in early PD.
[1] Lees AJ, Hardy J, Revesz T(2009). Parkinson's disease. Lancet, 373(9680):2055-2066.
[2] Weissmiller AM, Wu C (2012). Current advances in using neurotrophic factors to treat neurodegenerative disorders. Translational neurodegeneration, 1(1):14.
[3] Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & therapeutics, 138(2):155-175.
[4] Gomez-Pinilla F, Knauer DJ, Nieto-Sampedro M (1998). Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain research, 438(1-2):385-390.
[5] Iwakura Y, Piao YS, Mizuno M, et al (2005). Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. Journal of neurochemistry, 93(4):974-983.
[6] Grainne C.O Keeffe, Pam Tyers, Dag Aarslandet al (2009). Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. PNAS, 106: 8754-8759
[7] Pezzoli G, Zecchinelli A, Ricciardi S, et al (1991). Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. Movement disorders: official journal of the Movement Disorder Society, 6(4):281-287.
[8] Chen-Plotkin AS, Hu WT, Siderowf A, et al (2011). Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of neurology, 69(4):655-663.
[9] Kuhlenbäumer G, Hopfner F, Deuschl G (2014).Genetics of essential tremor: meta-analysis and review.Neurology, 82(11):1000-7.
[10] Delay C, Tremblay C, Brochu E, et al (2014).Increased LINGO1 in the cerebellum of essential tremor patients.Mov Disord. Feb 14. [Epub ahead of print]
[11] Inoue H, Lin L, Lee X, et al (2007). Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.PNAS, 104(36):14430-14435.
[12] Deuschl G, Bain P, Brin M (1998). Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Movement disorders: official journal of the Movement Disorder Society, 13 Suppl 3:2-23.
[13] Chen W, Chen S, Kang WY, et al (2012). Application of odor identification test in Parkinson's disease in China: a matched case-control study. Journal of the neurological sciences, 316(1-2):47-50.
[14] Booij J, Tissingh G, Boer GJ, et al (1997). [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 62(2):133-140.
[15] Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P (2013). The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Functional neurology, 28(1):13-17.
[16] Babij R, Lee M, Cortes E, Vonsattel JP, Faust PL, Louis ED (2013). Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains. Brain: a journal of neurology, 136(Pt 10):3051-3061.
[17] Birecree E, King LE, Jr., Nanney LB (1991). Epidermal growth factor and its receptor in the developing human nervous system. Brain research Developmental brain research, 60(2):145-154.
[18] Kuo SH, Tang G, Louis ED, et al (2013). Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta neuropathologica, 125(6):879-889.
[19] Zhou ZD, Sathiyamoorthy S, Tan EK (2012). LINGO-1 and Neurodegeneration: Pathophysiologic Clues for Essential Tremor. Tremor and other hyperkinetic movements, 2.pii: tre-02-51-249-1.
[20] Pellecchia MT, Santangelo G, Picillo M, et al (2013). Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. Journal of neurology, 260(2):438-444.
[21] Rocha NP, Teixeira AL, Scalzo PL, et al (2014). Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 29(4):527-31.
[1] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[2] De Lazzari Federica, Bubacco Luigi, Whitworth Alexander J, Bisaglia Marco. Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 716-728.
[3] Zhang Li, Hao Junwei, Zheng Yan, Su Ruijun, Liao Yajin, Gong Xiaoli, Liu Limin, Wang Xiaomin. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(4): 590-604.
[4] Perez-Roca Laia, Adame-Castillo Cristina, Campdelacreu Jaume, Ispierto Lourdes, Vilas Dolores, Rene Ramon, Alvarez Ramiro, Gascon-Bayarri Jordi, Serrano-Munoz Maria A., Ariza Aurelio, Beyer Katrin. Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood[J]. Aging and disease, 2018, 9(2): 208-219.
[5] Zhang Meng, Deng Yong-Ning, Zhang Jing-Yi, Liu Jie, Li Yan-Bo, Su Hua, Qu Qiu-Min. SIRT3 Protects Rotenone-induced Injury in SH-SY5Y Cells by Promoting Autophagy through the LKB1-AMPK-mTOR Pathway[J]. Aging and disease, 2018, 9(2): 273-286.
[6] Sun Qian, Wang Tian, Jiang Tian-Fang, Huang Pei, Wang Ying, Xiao Qin, Liu Jun, Chen Sheng-Di. Clinical Profile of Chinese Long-Term Parkinson’s Disease Survivors With 10 Years of Disease Duration and Beyond[J]. Aging and disease, 2018, 9(1): 8-16.
[7] Lv Deyong, Li Jingbo, Li Hongfu, Fu Yu, Wang Wei. Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson’s Disease Using Tracer-based MRI[J]. Aging and disease, 2017, 8(1): 1-6.
[8] Su Ruijun, Sun Min, Wang Wei, Zhang Jianliang, Zhang Li, Zhen Junli, Qian Yanjing, Zheng Yan, Wang Xiaomin. A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model[J]. Aging and disease, 2017, 8(1): 31-43.
[9] Smirnova Natalya A., Kaidery Navneet Ammal, Hushpulian Dmitry M., Rakhman Ilay I., Poloznikov Andrey A., Tishkov Vladimir I., Karuppagounder Saravanan S., Gaisina Irina N., Pekcec Anton, Leyen Klaus Van, Kazakov Sergey V., Yang Lichuan, Thomas Bobby, Ratan Rajiv R., Gazaryan Irina G.. Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson’s Disease[J]. Aging and disease, 2016, 7(6): 745-762.
[10] Sun Qian, Wang Tian, Jiang Tian-Fang, Huang Pei, Li Dun-Hui, Wang Ying, Xiao Qin, Liu Jun, Chen Sheng-Di. Effect of a Leucine-rich Repeat Kinase 2 Variant on Motor and Non-motor Symptoms in Chinese Parkinson’s Disease Patients[J]. Aging and disease, 2016, 7(3): 230-236.
[11] Claassen Daniel O., Dobolyi David G., Isaacs David A., Roman Olivia C., Herb Joshua, Wylie Scott A., Neimat Joseph S., Donahue Manus J., Hedera Peter, Zald David H., Landman Bennett A., Bowman Aaron B., Dawant Benoit M., Rane Swati. Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson’s Disease[J]. Aging and disease, 2016, 7(3): 220-229.
[12] Sterling Nicholas W., Lichtenstein Maya, Lee Eun-Young, Lewis Mechelle M., Evans Alicia, Eslinger Paul J., Du Guangwei, Gao Xiang, Chen Honglei, Kong Lan, Huang Xuemei. Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease[J]. Aging and disease, 2016, 7(3): 237-245.
[13] Yalcin Ahmet, Atmis Volkan, Karaarslan Cengiz Ozlem, Cinar Esat, Aras Sevgi, Varli Murat, Atli Teslime. Evaluation of Cardiac Autonomic Functions in Older Parkinson’s Disease Patients: a Cross-Sectional Study[J]. Aging and disease, 2016, 7(1): 28-35.
[14] Zhiguo Chen. Cell Therapy for Parkinson’s Disease: New Hope from Reprogramming Technologies[J]. A&D, 2015, 6(6): 499-503.
[15] Claudia Rangel-Barajas,Israel Coronel,Benjamín Florán. Dopamine Receptors and Neurodegeneration[J]. A&D, 2015, 6(5): 349-368.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd